Flu still ‘Texas big’ in the Lone Star and neighboring states
ATLANTA — For the week ended Feb. 2, influenza activity remained elevated in the United States but decreased in most areas, the Centers for Disease Control and Prevention reported Friday. According to CDC’s activity level map, it appears most incidence is concentrated across the central United States, including Texas, Oklahoma, Kansas and Missouri.
The proportion of outpatient visits for influenza-like illness nationwide was 3.6%, still above the national baseline of 2.2%.
A total of 19 states New York City were still reporting high ILI activity. Twelve states reported moderate ILI activity, and 13 states experienced low ILI activity.
Florida, Kentucky, Maine, Montana, New Hampshire and South Carolina all reported minimal activity.
Kimberly-Clark increasing face mask production due to higher demand because of the flu
ROSWELL, Ga. — Kimberly-Clark on Friday announced its continued increase in production of face masks and other personal protective equipment products in response to increased customer demand from acute care facilities across the country.
"The health and safety of our valued customers and their patients is our most important priority," stated John Amat, VP sales and marketing, Kimberly-Clark Health Care. "Kimberly-Clark representatives are proactively reaching out to all of our current customers to assure them that with our North America-based product supply, we can continue to provide the highest quality facial protection products throughout the flu season."
In support of clinicians, Kimberly-Clark also offers complimentary, accredited clinical education webinars on the topic of flu via The Kimberly-Clark Knowledge Network.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news.
Sanofi: Rolaids will be relieving heartburn with its return to the market by the end of the year
PARIS — During a quarterly conference call Thursday, Sanofi president of global operations Hanspeter Spek noted that Sanofi’s consumer arm Chattem will be relaunching the heartburn remedy Rolaids.
"We plan to relaunch the product, which has been absent of the American markets for production problems on the side of J&J," he told analysts. "We intend to launch the product by the end of 2013, which will further accelerate the performance of Chattem in the United States."
Sanofi has been very pleased with Chattem, Spek said, noting that Sanofi is now the third-largest consumer healthcare company globally behind Johnson & Johnson and Bayer. "The portfolio is growing by 9.9%, which is a good growth, I believe. The overall OTC market is growing in 2012 about 4%, 4.5%," he said.